GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » Net Income (Continuing Operations)

Median Technologies (XPAR:ALMDT) Net Income (Continuing Operations) : €-22.98 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Median Technologies Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Median Technologies's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was €-12.89 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was €-22.98 Mil.


Median Technologies Net Income (Continuing Operations) Historical Data

The historical data trend for Median Technologies's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Technologies Net Income (Continuing Operations) Chart

Median Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.99 -12.80 -19.29 -20.22 -22.98

Median Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.09 -8.88 -11.34 -10.09 -12.89

Median Technologies Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-22.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Median Technologies  (XPAR:ALMDT) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Median Technologies Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Median Technologies's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Median Technologies (XPAR:ALMDT) Business Description

Traded in Other Exchanges
Address
1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.

Median Technologies (XPAR:ALMDT) Headlines

No Headlines